TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484
Debt
Debt-to-Equity RatioN/A
Current Ratio3.51
Quick Ratio3.51
Price-To-Earnings
Trailing P/E Ratio-7.17
Forward P/E Ratio-6.61
P/E GrowthN/A
Sales & Book Value
Annual Sales$150,000.00
Price / Sales7,052.44
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book14.34
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-118,470,000.00
Net Margins-87,025.00%
Return on Equity-170.83%
Return on Assets-125.58%
Miscellaneous
Employees75
Outstanding Shares77,670,000
TG Therapeutics Inc common stock (NASDAQ:TGTX) Frequently Asked Questions
What is TG Therapeutics Inc common stock's stock symbol?
TG Therapeutics Inc common stock trades on the NASDAQ under the ticker symbol "TGTX."
How were TG Therapeutics Inc common stock's earnings last quarter?
TG Therapeutics Inc common stock (NASDAQ:TGTX) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.15. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics Inc common stock had a negative net margin of 87,025.00% and a negative return on equity of 170.83%. View TG Therapeutics Inc common stock's Earnings History.
What price target have analysts set for TGTX?
4 equities research analysts have issued 12 month price objectives for TG Therapeutics Inc common stock's stock. Their forecasts range from $27.00 to $33.00. On average, they anticipate TG Therapeutics Inc common stock's stock price to reach $29.3333 in the next twelve months. View Analyst Ratings for TG Therapeutics Inc common stock.
What are Wall Street analysts saying about TG Therapeutics Inc common stock stock?
Here are some recent quotes from research analysts about TG Therapeutics Inc common stock stock:
- 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (5/10/2018)
- 2. Raymond James analysts commented, "We are maintaining our Strong Buy rating for TG Therapeutics. Today, at the American Academy of Neurology (AAN) 70th Annual Meeting, the company provided an update on the ongoing Phase II study of TG-1101 (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS)." (4/25/2018)
- 3. HC Wainwright analysts commented, "TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of Novel BTK Inhibitors TG licenses novel BTK inhibitors that demonstrate superior selectivity to BTK in comparison to ibrutinib in the preclinical setting. On the morning of January 8, TG Therapeutics announced that it has entered into an exclusive global license agreement with Jiangsu Hengrui Medicine, pursuant to which TG will obtain worldwide rights, excluding Asia but including Japan, for the development of Hengrui’s BTK inhibitor program. The program includes TG-1701 and TG-1702, both of which are orally-available, covalently-bound BTK inhibitors." (1/8/2018)
Who are some of TG Therapeutics Inc common stock's key competitors?
Some companies that are related to TG Therapeutics Inc common stock include Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), HUTCHISON CHINA/S (HCM), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO) and OPKO Health (OPK).
Who are TG Therapeutics Inc common stock's key executives?
TG Therapeutics Inc common stock's management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman, Chief Exec. Officer and Pres (Age 52)
- Mr. Sean A. Power CPA, Chief Financial Officer, Corp. Sec. and Treasurer (Age 36)
- Jenna Bosco, Director of Investor Relations
Has TG Therapeutics Inc common stock been receiving favorable news coverage?
News stories about TGTX stock have been trending somewhat positive on Friday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TG Therapeutics Inc common stock earned a news impact score of 0.03 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 43.84 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are TG Therapeutics Inc common stock's major shareholders?
TG Therapeutics Inc common stock's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (6.92%), BlackRock Inc. (4.60%), Franklin Resources Inc. (3.19%), Columbus Circle Investors (1.01%), Northern Trust Corp (0.83%) and Point72 Asset Management L.P. (0.80%). Company insiders that own TG Therapeutics Inc common stock stock include Laurence N Charney, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics Inc common stock.
Which major investors are selling TG Therapeutics Inc common stock stock?
TGTX stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, JPMorgan Chase & Co., Artal Group S.A., Guggenheim Capital LLC, Franklin Resources Inc., Citigroup Inc., United Capital Financial Advisers LLC and BB&T Securities LLC. Company insiders that have sold TG Therapeutics Inc common stock company stock in the last year include Sean A Power and William James Kennedy. View Insider Buying and Selling for TG Therapeutics Inc common stock.
Which major investors are buying TG Therapeutics Inc common stock stock?
TGTX stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Point72 Asset Management L.P., Highland Capital Management LP, Millennium Management LLC, Opaleye Management Inc., Columbus Circle Investors, Eversept Partners LLC and UBS Group AG. View Insider Buying and Selling for TG Therapeutics Inc common stock.
How do I buy shares of TG Therapeutics Inc common stock?
Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TG Therapeutics Inc common stock's stock price today?
One share of TGTX stock can currently be purchased for approximately $13.62.
How big of a company is TG Therapeutics Inc common stock?
TG Therapeutics Inc common stock has a market capitalization of $1.13 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-118,470,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics Inc common stock employs 75 workers across the globe.
How can I contact TG Therapeutics Inc common stock?
TG Therapeutics Inc common stock's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]
MarketBeat Community Rating for TG Therapeutics Inc common stock (TGTX)
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics Inc common stock and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
